Key facts
- This page summarizes Alfred D. Kingsley's Form 4 filing for Lineage Cell Therapeutics, Inc. (LCTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Jul 2023, 17:46.
Alfred D. Kingsley - 01 Jul 2023 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)
- Reporting relationship
- Chairman, Director
- Issuer ticker
- LCTX
- Reported as of
- 01 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jul 2023, 17:46:00 UTC
- Prior SEC filing
- 27 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alexandra Hernandez, as Attorney-in Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Alfred D. Kingsley filed Form 4 for Lineage Cell Therapeutics, Inc. (LCTX) on 03 Jul 2023.
Change
- Previous filing in this sequence was filed on 27 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LCTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 01 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 50,000
- Exercise price
- $1.41
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Will vest and become exercisable on July 1, 2024, subject to the reporting person's continuous service with the issuer.